Children (Newborn to 12 years)
Active Resources: 7
Primary Care Guidelines
-
11/9/2015
Webinars
-
4/17/2015
Antiretroviral Guidelines
-
3/3/2015 (reviewed: 4/27/2017)
Charts, Tables & Posters
-
11/24/2014
Prevention & Testing Guidelines (PEP, PrEP, PWP)
-
1/1/2014
OIs & Complications Guidelines
-
11/6/2013 (reviewed: 12/15/2016)
Patient Information
-
1/1/2013
Archive Resources: 7
Patient Information
-
1/1/2010
-
9/1/2006
Slide Sets
-
7/1/2009
-
6/1/2006
Self-Study Materials
-
1/1/2004
Articles: 3
-
FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics
The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.
It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...
-
Once-Daily Dosing of Lamivudine and Abacavir for Pediatric Patients
The U.S. Food and Drug Administration has approved once-daily dosing recommendations for lamivudine and abacavir for HIV-infected children. Previously, these NRTIs were approved only for twice-daily dosing in children. The dosing revisions apply to both the oral solution and the tablet...
-
Fast Takes: Darunavir Once-Daily Dosing for Children
The FDA recently approved revisions to the pediatric dosing recommendations for darunavir tablets and oral suspension. Once-daily dosing of darunavir + ritonavir is recommended for children 3 years of age and older, and >10 kg in weight, who are treatment naive or whose HIV virus does not...
| Day | Title |
|---|---|
|
9/22 |
|
|
3/7 |
|
|
1/23 |